- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05384769
Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer
Feasibility Study of Lung Cancer Screening Using Cell-Free DNA Liquid Biopsy at Home in High-Risk Current and Former Smokers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the feasibility of lung cancer screening using liquid biopsy in a community setting.
SECONDARY OBJECTIVES:
I. To determine screening follow-through rates in those who agreed to undergo screening by preferred modality (liquid biopsy versus [vs] LDCT).
II. To determine the rate of LDCT following liquid biopsy (in those who underwent liquid biopsy) after stratifying by test result (negative versus positive).
III. To compare participant sociodemographic factors (age, sex, race/ethnicity, educational background) and survey scores across screening preference (liquid biopsy vs. LDCT).
OUTLINE: Participants choose 1 of 2 cohorts.
COHORT A: Participants undergo collection of blood sample (liquid biopsy), with option to undergo LDCT if liquid biopsy results are positive.
COHORT B: Participants undergo low dose CT with optional liquid biopsy on the same day as LDCT.
After completion of study, patients are followed up at 6 months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Medical Center
-
Contact:
- Dan Raz
- Phone Number: 626-256-4673
- Email: draz@coh.org
-
Principal Investigator:
- Dan Raz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Documented written informed consent of the participant.
- Age 50-80 years.
- Smoking history of >= 20 pack-years and if quit, quit within 15 years.
- Received referral for counseling for lung cancer screening and would qualify for LDCT.
- Health Insurance that will pay for a LDCT for lung cancer screening at either City of Hope Duarte, Newport Beach (Newport Diagnostic Imaging), or Lancaster (Renaissance Imaging/Antelope Valley Outpatient Imaging Center).
- Willingness to provide blood sample.
- English speaking.
- Consent to undergo lung cancer screening with either liquid biopsy (LB) or LDCT.
Exclusion Criteria:
- Symptoms of lung cancer.
- Chest CT scan or chest positron emission tomography (PET)/CT within 12 months.
- Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer.
- Unable to undergo LDCT at either City of Hope Duarte, Newport Beach, or Lancaster.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A (liquid biopsy, optional LDCT)
Participants undergo collection of blood sample (liquid biopsy), with option to undergo LDCT if liquid biopsy results are positive.
|
Ancillary studies
Undergo liquid biopsy
Other Names:
Undergo low dose CT
Other Names:
|
Experimental: Cohort B (LDCT, optional liquid biopsy)
Participants undergo low dose CT with optional liquid biopsy on the same day as LDCT.
|
Ancillary studies
Undergo liquid biopsy
Other Names:
Undergo low dose CT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Screening preference
Time Frame: Upon completion of home liquid biopsy or LDCT, an average of 4 weeks.
|
The proportion of participants who agree to undergo lung cancer screening using liquid biopsy versus LDCT, with a feasibility threshold of at least 30% preferring liquid biopsy.
|
Upon completion of home liquid biopsy or LDCT, an average of 4 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants who follow-through on screening 1
Time Frame: 6 month follow-up timepoint.
|
The proportion of participants who are screened with LDCT at 6 months in each screening group.
|
6 month follow-up timepoint.
|
Participants who follow-through on screening 2
Time Frame: 6 month follow-up timepoint.
|
The proportion of participants who undergo LDCT at 6 months after receiving liquid biopsy results, stratified by test result (negative vs positive).
|
6 month follow-up timepoint.
|
Participants who follow-through on screening 3
Time Frame: 6 month follow-up timepoint.
|
Differences in sociodemographic factors across screening preference (liquid biopsy vs. LDCT) in those who undergo screening (Exploratory).
|
6 month follow-up timepoint.
|
Participants who follow-through on screening 4
Time Frame: 6 month follow-up timepoint.
|
Differences in sociodemographic survey scores across screening preference (liquid biopsy vs. LDCT) in those who undergo screening (Exploratory).
|
6 month follow-up timepoint.
|
Participants who undergo low dose computed tomography of the chest (LDCT) after receiving liquid biopsy results
Time Frame: Up to 6 months
|
For those who choose liquid biopsy only.
Data will be summarized using counts and percentages and tested using Chi-square analysis.
|
Up to 6 months
|
Sociodemographic factors (age, sex, race/ethnicity, educational background)
Time Frame: At baseline visit
|
Data will be summarized using means and standard deviations or counts and percentages, depending on whether the data are continuous or categorical.
Univariate tests across groups will be done using t-tests (continuous) and chi-square analysis (categorical).
Non-parametric tests will be used for continuous data that are non-normally distributed data (Kruskal-Wallis) and for ordinal categorical data (Jonckheere-Terpstra).
Multivariable logistic regression methods will be used to determine the primary factors predicting screening preference.
Data included in the model will be determined based on clinical relevance and/or significance in univariate analysis.
|
At baseline visit
|
Survey scores across screening preference 1
Time Frame: At 6 month follow up
|
Survey tools will be used to understand sociodemographics, prior cancer screening, cancer worry, lung cancer risk perception, and barriers to lung cancer screening. Survey tools utilized:Demographics tool: including sex, race/ethnicity, education level, income. |
At 6 month follow up
|
Survey scores across screening preference 2
Time Frame: At 6 month follow up
|
Survey tools will be used to understand sociodemographics, prior cancer screening, cancer worry, lung cancer risk perception, and barriers to lung cancer screening. Survey tools utilized: Tobacco smoking history |
At 6 month follow up
|
Survey scores across screening preference 3
Time Frame: At 6 month follow up
|
Survey tools will be used to understand sociodemographics, prior cancer screening, cancer worry, lung cancer risk perception, and barriers to lung cancer screening. Survey tools utilized: Prior use of colon, breast, and lung cancer screening. |
At 6 month follow up
|
Survey scores across screening preference 4
Time Frame: At 6 month follow up
|
Survey tools will be used to understand sociodemographics, prior cancer screening, cancer worry, lung cancer risk perception, and barriers to lung cancer screening. Survey tools utilized: Lung Cancer Screening Health Beliefs Survey (lung cancer risk perception and barriers to lung cancer screening). |
At 6 month follow up
|
Survey scores across screening preference 5
Time Frame: At 6 month follow up
|
Survey tools will be used to understand sociodemographics, prior cancer screening, cancer worry, lung cancer risk perception, and barriers to lung cancer screening. Survey tools utilized: Cancer Worry Scale |
At 6 month follow up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dan Raz, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21591 (Other Identifier: City of Hope Medical Center)
- P30CA033572 (U.S. NIH Grant/Contract)
- NCI-2022-02513 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Carcinoma
-
National Cancer Institute (NCI)CompletedLung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Adenosquamous Lung Carcinoma | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma | Squamous Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
University Hospital, LimogesGroupe Français de Pneumologie Cancérologie (GFPC)CompletedNon Small Cell Lung CarcinomaFrance
-
Massachusetts General HospitalCompletedSmall Cell Lung Carcinoma | Non-small Cell Lung CarcinomaUnited States
-
Shenzhen People's HospitalUnknownCarcinoma, Non-Small Cell Lung | Carcinoma, Small Cell LungChina
-
Pathway GenomicsTerminatedLung Neoplasms | Lung Cancer | Adenocarcinoma of the Lung | Cancer of the Lung | Small Cell Carcinoma of the Lung | Non Small Cell Carcinoma of the LungUnited States
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Survey Administration
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Boston UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingAcute Lymphoblastic LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | COVID-19 Infection | Recurrent Hematologic MalignancyUnited States
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Pancreatic Neuroendocrine CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States